These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 6652914)
1. Immunoradiometric assay for human complement component C9 utilising monoclonal antibodies. Morgan BP; Campbell AK; Luzio JP; Siddle K Clin Chim Acta; 1983 Oct; 134(1-2):85-94. PubMed ID: 6652914 [TBL] [Abstract][Full Text] [Related]
2. The ninth complement component in rheumatoid arthritis, Behçet's disease and other rheumatic diseases. Rumfeld WR; Morgan BP; Campbell AK Br J Rheumatol; 1986 Aug; 25(3):266-70. PubMed ID: 3488089 [TBL] [Abstract][Full Text] [Related]
3. Complement component C9 in Graves' disease. Oleesky DA; Ratanachaiyavong S; Ludgate M; Morgan BP; Campbell AK; McGregor AM Clin Endocrinol (Oxf); 1986 Dec; 25(6):623-32. PubMed ID: 3308182 [TBL] [Abstract][Full Text] [Related]
4. Measurement of C9 concentrations using an immunochemiluminometric assay. Weeks I; Morgan BP; Campbell AK; Woodhead JS J Immunol Methods; 1985 Jun; 80(1):33-8. PubMed ID: 4008938 [TBL] [Abstract][Full Text] [Related]
5. Terminal component of complement (C9) in cerebrospinal fluid of patients with multiple sclerosis. Morgan BP; Campbell AK; Compston DA Lancet; 1984 Aug; 2(8397):251-4. PubMed ID: 6146808 [TBL] [Abstract][Full Text] [Related]
6. A unique epitope exposed in native complement component C9 and hidden in the terminal SC5b-9 complex enables selective detection and quantification of non-activated C9. Mollnes TE; Tschopp J J Immunol Methods; 1987 Jun; 100(1-2):215-21. PubMed ID: 2439601 [TBL] [Abstract][Full Text] [Related]
7. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Mollnes TE; Lea T; Frøland SS; Harboe M Scand J Immunol; 1985 Aug; 22(2):197-202. PubMed ID: 2412280 [TBL] [Abstract][Full Text] [Related]
8. Immunoaffinity purification of human complement component C9 using monoclonal antibodies. Morgan BP; Daw RA; Siddle K; Luzio JP; Campbell AK J Immunol Methods; 1983 Nov; 64(3):269-81. PubMed ID: 6199425 [TBL] [Abstract][Full Text] [Related]
9. Immunolocalization of complement component C9 on necrotic and non-necrotic muscle fibres in myositis using monoclonal antibodies: a primary role of complement in autoimmune cell damage. Morgan BP; Sewry CA; Siddle K; Luzio JP; Campbell AK Immunology; 1984 May; 52(1):181-8. PubMed ID: 6370840 [TBL] [Abstract][Full Text] [Related]
10. Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. Falk RJ; Dalmasso AP; Kim Y; Tsai CH; Scheinman JI; Gewurz H; Michael AF J Clin Invest; 1983 Aug; 72(2):560-73. PubMed ID: 6348093 [TBL] [Abstract][Full Text] [Related]
11. Terminal component of complement (C9) in the cerebrospinal fluid of patients with multiple sclerosis and neurologic controls. Rodriguez M; Wynn DR; Kimlinger TK; Katzmann JA Neurology; 1990 May; 40(5):855-7. PubMed ID: 2330118 [TBL] [Abstract][Full Text] [Related]
12. A haemolytic assay for the measurement of C9 in human serum and cerebrospinal fluid. Asghar SS; Siem H; van der Helm HJ Clin Chim Acta; 1987 Jun; 165(2-3):387-90. PubMed ID: 3652460 [No Abstract] [Full Text] [Related]
13. Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies. Kemp PA; Spragg JH; Brown JC; Morgan BP; Gunn CA; Taylor PW J Clin Lab Immunol; 1992; 37(4):147-62. PubMed ID: 1285067 [TBL] [Abstract][Full Text] [Related]
14. A high incidence of C9 deficiency among healthy blood donors in Osaka, Japan. Fukumori Y; Yoshimura K; Ohnoki S; Yamaguchi H; Akagaki Y; Inai S Int Immunol; 1989; 1(1):85-9. PubMed ID: 2487678 [TBL] [Abstract][Full Text] [Related]
15. Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane. Konttinen YT; Ceponis A; Meri S; Vuorikoski A; Kortekangas P; Sorsa T; Sukura A; Santavirta S Ann Rheum Dis; 1996 Dec; 55(12):888-94. PubMed ID: 9014582 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of complement-induced [14C]sucrose release by intracellular and extracellular monoclonal antibodies to C9: evidence that C9 is a transmembrane protein. Morgan BP; Luzio JP; Campbell AK Biochem Biophys Res Commun; 1984 Jan; 118(2):616-22. PubMed ID: 6704099 [TBL] [Abstract][Full Text] [Related]
17. Deficiency of the human complement regulatory protein factor H associated with low levels of component C9. Falcão DA; Reis ES; Paixão-Cavalcante D; Amano MT; Delcolli MI; Florido MP; Albuquerque JA; Moraes-Vasconcelos D; Duarte AJ; Grumach AS; Isaac L Scand J Immunol; 2008 Oct; 68(4):445-55. PubMed ID: 18782275 [TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies directed against gonococcal protein I vary in bactericidal activity. Joiner KA; Warren KA; Tam M; Frank MM J Immunol; 1985 May; 134(5):3411-9. PubMed ID: 3920319 [TBL] [Abstract][Full Text] [Related]
19. Rapid isolation of human complement component C9 to verify the specificity of a haemolytic C9 microassay. Bootsma HJ; van den Berg CW; van Dijk H J Chromatogr; 1992 Feb; 591(1-2):187-93. PubMed ID: 1613052 [TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies against neoantigens of the terminal C5b-9 complex of human complement. Hugo F; Jenne D; Bhakdi S Biosci Rep; 1985 Aug; 5(8):649-58. PubMed ID: 2415178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]